BUFFALO, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...

ASPEN – Aspen-based FM radio station KUUR, “Your Radio,” has geared up for the holiday season and will go full-blown with seasonal-music only from Dec. 14-25 with its “12 Days of Christmas Music.” For ...

(RTTNews) - Athenex, Inc. (ATNX) has acquired Kuur Therapeutics, Inc., a developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies. Kuur ...

HOUSTON--(BUSINESS WIRE)--Kuur Therapeutics today announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based ...

Biopharmaceutical company Athenex Inc. (ATNX) is acquiring Kuur Therapeutics for a total consideration of $185 million. The latter develops CAR-NKT cell immunotherapies targeted at solid and ...

Ziopharm Oncology is refreshing its CEO post with a new leader, nabbing former Kuur Therapeutics CEO Kevin S. Boyle for the top spot. The cell and gene therapies biotech also promoted Chief Medical ...

HOUSTON--(BUSINESS WIRE)--Kuur Therapeutics, the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced clinical ...

Cell Medica has rebranded as Kuur Therapeutics, pulling in fresh funds from IP Group, Baylor College of Medicine and Schroder Adveq along the way. Kuur will use the money to fund phase 1 trials of ...

In the spirit of the season, KUUR(FM) in Aspen, Colo. is working with Radio Mawwal 101.7 FM in Bethlehem to provide Christmas programming. A release explains, “The station typically airs world music ...

Transformative, leading allogeneic NKT cell platform technology expands Athenex's cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric ...

Biopharmaceutical company Athenex Inc. (ATNX) is acquiring Kuur Therapeutics for a total consideration of $185 million. The latter develops CAR-NKT cell immunotherapies targeted at solid and ...

In 2016, Kuur Therapeutics and BCM signed an exclusive licensing and co-development agreement around cellular immunotherapy products for the treatment of cancer. The co-development collaboration has ...